Gene-defined cancer-origin cell and a classification method thereof

• Main Authors: YOON SEONJIN, KANG SEOK GU, CHOI RANJOO
• Format: Patent
• Language: English; Korean
• Published: 17.10.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; TESTING; VINEGAR; WINE

본 발명은 뇌실하대로부터 분리된 세포에서 NRXN1, XKR4, MAP2, SLC1A2, MEG3, TNR, NRCAM, PTPRZ1, LUZP2, RORA, PLP1, TF, MBP, CERCAM, TMEM144, PLXDC2, FTL, 및 LAMA2 로 구성된 군으로부터 선택되는 하나 이상의 단백질, 또는 이를 코딩하는 유전자의 발현 정도를 확인하는 단계를 포함하는, 뇌암 기원 세포의 분리 방법에 관한 것이다. 본 발명자들은 뇌암, 특히 유효한 치료제의 발굴이 어렵고 예후와 생존률이 매우 불량한 교모세포종에 있어서, 상기 인자들이 신뢰도 높은 진단 표지자로 기능할 뿐 아니라, 이들의 발현 조절을 통해 종양을 억제하여 난치성 질환인 교모세포종 환자의 생존률을 현저히 개선하는 근본적인 치료제 조성물로 유용하게 이용될 수 있다. The present invention relates to a method for isolating brain cancer progenitor cells, comprising a step of identifying, in cells isolated from the subventricular zone, the expression level of: one or more proteins selected from the group consisting of NRXN1, XKR4, MAP2, SLC1A2, MEG3, TNR, NRCAM, PTPRZ1, LUZP2, RORA, PLP1, TF, MBP, CERCAM, TMEM144, PLXDC2, FTL, and LAMA2; or genes encoding same. The inventors have identified that, in brain cancer, especially in glioblastoma, in which discovery of effective therapeutic agents is difficult and of which prognosis and survival rate are very poor, factors function as highly reliable diagnostic markers and tumors are inhibited through expression regulation of the factors, and thus the present invention can be effectively used as a fundamental therapeutic composition for remarkably improving the survival rate of patients with glioblastoma, which is an intractable disease.